Effects of interferon α treatment on the clinical course of refractory Behçet's disease: an open study
Open Access
- 1 May 2003
- journal article
- letter
- Published by Elsevier in Annals of the Rheumatic Diseases
- Vol. 62 (5) , 492-493
- https://doi.org/10.1136/ard.62.5.492
Abstract
A total of 29 patients (17 men, 12 women; mean age 33.2 months, range 16–51) who were resistant to conventional treatments were treated with systemic IFNα. Previous conventional treatments had been colchicine, aspirin, and penicillin plus sulfasalazine for patients with arthritis; or colchicine, aspirin, and penicillin plus steroids and/or immunosuppressive agents, azathioprine, cyclosporin A, or cyclophosphamide for ocular, vascular, and/or neurological involvement. The mean duration of the disease was 8.86 years (range 1–30). Four patients were excluded from the statistical analysis because of the short duration of treatment (<4 months).Keywords
This publication has 7 references indexed in Scilit:
- Interferon-Alpha 2a Treatment of Neuro-Behcet DiseaseJournal of Neuro-Ophthalmology, 2001
- Treatment of Adamantiades-Behçet Disease With Systemic Interferon AlfaArchives of Dermatology, 1998
- Efficacy and safety of systemic recombinant interferon‐alpha in Behcet's diseaseJournal of Internal Medicine, 1998
- Treatment of ocular symptoms of Behcet's disease with interferon alpha 2a: a pilot studyBritish Journal of Ophthalmology, 1998
- Interferon α for ocular Behçet's diseaseActa Ophthalmologica Scandinavica, 1997
- Interteron alfa-2a in the Treatment of Behçet’s DiseaseDermatology, 1996
- Interferon-Associated RetinopathyArchives of Ophthalmology (1950), 1993